Innovative drug approvals vs Clinical trial country use share in China

Innovative drug approvals and Clinical trial country use share in China, compared over time.

Change the pair

Compare different indicators

The series

Over time

China, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Innovative drug approvals

Unit: count · 2 observations

Line chart
Innovative drug approvalsInnovative drug approvals. 2 observations from 2024 to 2025, ranging from 48 to 76. Latest value 76 (2025). 0 20 40 60 80 2019 2020 2021 2022 2023 2024 2025 48 76
Innovative drug approvalsInnovative drug approvals. 2 observations from 2024 to 2025, ranging from 48 to 76. Latest value 76 (2025). 0 30 60 90 2019 2020 2021 2022 2023 2024 2025 48 76
Innovative drug approvalsInnovative drug approvals. 2 observations from 2024 to 2025, ranging from 48 to 76. Latest value 76 (2025). 0 30 60 90 2019 2020 2021 2022 2023 2024 2025 48 76
View the underlying data
Innovative drug approvals
Period Type Value
2024 Actual 48
2025 Actual 76
Source: NHSA · CC BY 4.0 · Full series

Clinical trial country use share

Unit: % · 3 observations

Line chart
Clinical trial country use shareClinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023). % 0 3 6 9 12 15 2019 2020 2021 2022 2023 2024 2025 10% 15%
Clinical trial country use shareClinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023). % 0 5 10 15 2019 2020 2021 2022 2023 2024 2025 10% 15%
Clinical trial country use shareClinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023). % 0 5 10 15 2019 2020 2021 2022 2023 2024 2025 10% 15%
View the underlying data
Clinical trial country use share
Period Type Value
2019 Actual 10%
2021–2023 Actual 13%
2023 Actual 15%
Source: IQVIA · CC BY 4.0 · Full series

Provenance

Where these numbers come from

Innovative drug approvals

Total number of innovative pharmaceutical products granted regulatory marketing authorization.

2 observations in China · source organisations: NHSA

Clinical trial country use share

Percentage of total clinical trial country uses accounted for by a given region.

3 observations in China · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related